ArticleNature communications2021
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 241 citations in OpenAlex.
- Phase I, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, and Pharmacokinetics of BS1801 in Healthy Chinese Adult Subjects.Drug design, development and therapy · 2026Trial
- Insights into the complexity of SARS-CoV-2 MJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Design, synthesis and SARS-CoV‑2 main protease inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives.Molecular diversity · 2026Article
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Progress in the Synthesis of Organoselenium Compounds: Conventional Routes Versus Green Approaches.Molecules (Basel, Switzerland) · 2026Review
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- Unraveling the Physicochemical Landscape of Organoselenium Compounds in Nanocarrier Systems.Chemical record (New York, N.Y.) · 2026Review
- Novel NSAID-Se derivative YSN-1-167 against Enterovirus 71 infection by inhibiting 3DAntimicrobial agents and chemotherapy · 2026Article
- Targeting a Unique Cysteine Residue to Achieve Isoform-Selective Inhibition of the Proline Biosynthetic Enzyme Pyrroline-5-Carboxylate Reductase 2.ACS chemical biology · 2026Article
- Selenium-Based Strategies for Targeting Multidrug-Resistant Breast Cancer: A Review.International journal of molecular sciences · 2026Review
- Establishment of a green fluorescent protein (GFP)-based reporter for picornaviral 3C proteases.Journal of virology · 2026Article
- Structure- and Ligand-Based Discovery of Novel 3-Chymotrypsin-Like Protease Nonpeptidomimetic Hits.ChemMedChem · 2026Article
- Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease.Molecules (Basel, Switzerland) · 2026Review
- Article
- Synthetic Motifs for Understanding Lewis Acid Interactions with Persulfides and Thioselenides.Angewandte Chemie (International ed. in English) · 2026Article
- Broad-spectrum antiviral activity of ebselen.Scientific reports · 2025Article
- The novel thioredoxin reductase inhibitor butaselen suppresses lung cancer by inducing oxidative stress.Redox report : communications in free radical research · 2025Article
- Synthesis of Phosphonate Derivatives of Benzisoselenazolones and Their Remarkable Antiureolytic Activity inJournal of medicinal chemistry · 2025Article
- Discovery of Galloyl-Flavonoid Conjugates as SARS-CoV-2 3CLInternational journal of molecular sciences · 2025Article
- Redox regulation: mechanisms, biology and therapeutic targets in diseases.Signal transduction and targeted therapy · 2025Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main protease of SARS-CoV-2 (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.